Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Institut Pasteur de Lille, National University of Ireland Maynooth
InventorsCamille Locht, Bernard Mahon, Heather Kavanaugh
Life of this patent
Estimating the term…
Abstract
The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Claims6
A method for reducing serum levels of immunoglobulin E (IgE) antibodies specific for an antigen to which a subject has been sensitized, the method comprising infecting the antigen-sensitized subject's respiratory tract with a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT), wherein the step of infecting the antigen-sensitized subject's respiratory tract with the live Bordetella pertussis strain reduces the subject's serum levels of IgE.
Dependencies are inferred from the claim text.